What CDC Recommends for the 2026-27 Flu Season
In a September 1, 2026 update, the Centers for Disease Control and Prevention confirmed that its previous flu vaccination recommendations remain in place for the 2026-27 season. That means an annual flu vaccine continues to be advised for people age 6 months and older who do not have a contraindication, a group that includes all adults over 50.
This season’s vaccines have been fully reformulated to better match the flu viruses expected to circulate, including the H3N2 “subclade K” variant that spread widely last season. All U.S. influenza vaccines for 2026-27 are trivalent, containing two influenza type A strains and one influenza type B strain, and all three vaccine virus components changed from last season.
Why does this matter more after 50? As people age, their immune systems do not respond as strongly to infection, which is why adults 65 and older account for most flu-related hospitalizations and deaths. The flu vaccine does not guarantee you will avoid the flu, but it is one of the best-studied ways to reduce the risk of severe illness, hospitalization and death — and this season, adults over 50 have a new option that did not exist before.
One important note on timing: this guidance is from September 1, 2026, not a new announcement this week. It is trending again now because the end of October is the window CDC points to for getting vaccinated before flu activity typically rises in late fall and winter.
What’s New This Season: The First mRNA Flu Vaccine
In August 2026, the Food and Drug Administration approved mFLUSIVA (Moderna), the first mRNA influenza vaccine, for people age 50 years and older. It is the first flu vaccine in the United States built on mRNA technology, the same kind of technology used in some COVID-19 vaccines, which helps the immune system recognize and respond to influenza.
Unlike traditional flu vaccines that use egg-based manufacturing, mFLUSIVA is made using an egg-free process. The technology may also allow flu vaccines to be manufactured more quickly, which could give health officials greater flexibility as influenza viruses change from season to season.
Approval details differ by age group. The vaccine is fully approved for adults ages 50 to 64, and it has received accelerated approval for those 65 and older, pending additional study results. That distinction matters for the next question many older adults ask: which shot should they actually get?
For adults 50 to 64, mFLUSIVA is now one more option alongside the standard flu vaccines. For adults 65 and older, the CDC’s formal preferential recommendation still names three established options first, as explained below, while the American Academy of Family Physicians also includes the mRNA vaccine among its preferred options for people 65 and older. If you are unsure which product fits your situation, CDC guidance consistently points to the same step: talk with your healthcare provider about which flu vaccine is right for you.
Which Shot for Adults 65 and Older
For adults age 65 years and older, CDC preferentially recommends one of three enhanced vaccines instead of a standard-dose shot: the high-dose inactivated influenza vaccine (HD-IIV, sold as Fluzone High-Dose), the adjuvanted inactivated influenza vaccine (aIIV, sold as Fluad), or the recombinant influenza vaccine (RIV, sold as Flublok).
Each of these vaccines is designed differently, but all three produce a stronger immune response in older adults. Studies have not shown that one works better than the others, so there is no need to wait for a specific brand if another enhanced option is available. If none of the three is available at the time of the visit, CDC says any age-appropriate flu vaccine should be used — a standard-dose flu vaccine is still far better than no vaccine.
The same “enhanced first” idea appears in guidance from medical societies this season. The American Academy of Family Physicians recommends the high-dose, adjuvanted, recombinant, or new mRNA influenza vaccine preferentially for people age 65 and older. Separate seasonal recommendations from the American Academy of Pediatrics, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America all emphasize the benefits of routine annual influenza vaccination.
One practical point: Medicare Part B covers all FDA-approved seasonal flu vaccines for adults 65 and older, with no out-of-pocket cost when given by a Medicare-participating doctor, clinic or pharmacy. That coverage is a statutory benefit and does not depend on which product is preferentially recommended.
When to Get It, and What Else to Know
According to CDC, the ideal time to get a flu shot is at the start of the season, such as in mid-September or October, and CDC recommends flu vaccination by the end of October. The vaccine takes about two weeks to become fully effective, so getting it early means protection is in place when flu activity spikes in late fall and winter. Since immunity wanes over time, it is not recommended for older adults to get vaccinated much earlier than the season.
If you miss the end-of-October window, it is not too late. Even a flu shot in November or later can still provide valuable protection, and CDC notes that people who miss the window can still benefit from getting vaccinated. Flu vaccines are updated each year, so last season’s shot does not carry over — this season’s reformulated vaccine is the one matched to the viruses expected now.
It is also worth keeping flu in context with other seasonal health steps. Older adults are often advised to check whether they are up to date on other vaccines, including RSV, pneumonia and shingles, depending on their health situation — again, a question for a healthcare provider rather than a one-size-fits-all answer. And when health agencies issue safety warnings, such as the recent FDA warning on Haifa smoked fish or the recall of GLP-1 injections, those notices are separate from vaccination guidance and apply to specific products only.
What we know: CDC’s 2026-27 recommendations are confirmed as of September 1, 2026; mFLUSIVA is FDA-approved for adults 50 and older; and three enhanced vaccines are preferentially recommended at 65 and up. What we don’t know yet: how the new mRNA vaccine will compare head-to-head with the established high-dose option in real-world use over a full season, since no head-to-head trial has compared them directly — one reason the 65-and-older approval remains accelerated pending further study.
The bottom line for adults over 50 this fall is straightforward: this season brings the same annual recommendation, a reformulated vaccine matched to the viruses circulating now, and — for the first time — an mRNA option. The best next step is a short conversation with your doctor, clinic or pharmacist about which product is available and right for you, ideally before the end of October.
